Value through Innovation27 July 2016

Clinical Study Results

  • PRADAXA ® - Atrial Fibrillation
    Clinical Study Number 1160.204
    Study Indication Atrial Fibrillation
    Product PRADAXA ®
    Generic Name Dabigatran
    Lab Code
    Clinical Phase IV
    Study Title

    Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The RE-CIRCUIT Trial)

    Study Document Lay summary 1160.204 english
  • PRADAXA ® - Atrial Fibrillation
    Clinical Study Number 1160.186
    Study Indication Atrial Fibrillation
    Product PRADAXA ®
    Generic Name Dabigatran
    Lab Code
    Clinical Phase IIIb
    Study Title

    A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110 mg and 150 mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI)

    Study Document Lay summary 1160.186 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.